Monitoring white blood cell count in adult patients with schizophrenia who are taking clozapine: a cost-effectiveness analysis

Girardin, François; Poncet, Antoine; Blondon, Marc; Rollason, Victoria; Vernaz-Hegi, Nathalie; Chalandon, Yves; Dayer, Pierre; Combescure, Christophe

doi:10.1016/S2215-0366(14)70245-7

Advanced search

Browse by...

Deposit

Highlights

More informations

Title		Monitoring white blood cell count in adult patients with schizophrenia who are taking clozapine: a cost-effectiveness analysis
Authors		Girardin, François Poncet, Antoine Blondon, Marc Rollason, Victoria Vernaz-Hegi, Nathalie Chalandon, Yves Dayer, Pierre Combescure, Christophe
Published in		The Lancet. Psychiatry. 2014, vol. 1, no. 1, p. 55-62
Abstract		Long-term monitoring of white blood cell count is compulsory in patients taking clozapine, although the incidence of drug-induced agranulocytosis is lower than previously expected. The cost-effectiveness of this monitoring is unknown. We aimed to assess the cost-effectiveness of various strategies to monitor white blood cell count in adult patients with schizophrenia taking clozapine.
Identifiers		DOI: 10.1016/S2215-0366(14)70245-7 PMID: 26360402
Full text		Article (Published version) (1.6 MB) - Limited access to UNIGE
Structures		Faculté de médecine / Section de médecine clinique / Département de médecine Faculté de médecine / Section de médecine clinique / Département d'anesthésiologie, pharmacologie, soins intensifs et urgences Faculté de médecine / Section de médecine clinique / Département de santé et médecine communautaires
Research groups		Epidémiologie clinique (115) Groupe Desmeules Jules (pharmacologie/toxicologie) (567)
Citation (ISO format)		GIRARDIN, François et al. Monitoring white blood cell count in adult patients with schizophrenia who are taking clozapine: a cost-effectiveness analysis. In: The Lancet. Psychiatry, 2014, vol. 1, n° 1, p. 55-62. doi: 10.1016/S2215-0366(14)70245-7 https://archive-ouverte.unige.ch/unige:89789